TAILΦR (Tailored Antibacterials and Innovative Laboratories for phage (Φ) Research) Labs at Baylor College of Medicine, delivers personalized and effective treatments for challenging antibiotic-resistant bacterial infections by cultivating scientific and medical expertise, technology, and innovation to generate an expedited bench-to-bedside pipeline. They TAILOR infection and biocontrol for healthcare, animal care, agricultural and industrial settings.
TAILΦR provides personalized solutions for infectious disease and industrial biocontrol and develops new technologies that facilitate the discovery and evolution of novel phages with enhanced attributes for your unique applications. Through these efforts, they will compile the largest characterized library of therapeutic phages for all major drug-resistant bacterial species. TAILΦR aims to kick-start an adaptable medicine revolution, wielding the same weapon that empowers diseases to resist traditional treatments: directed change.
TAILΦR is a non-profit initiative providing at-cost services designed to help the most pressing medical and industrial needs that are threatened by bacterial infection or contamination. The TAILΦR team strives to provide:
Safe, targeted antibacterial products that are thoroughly characterized and documented.
Quantitative and reproducible results that can be trusted and verified.
Transparent collaborations with a team-like culture that meet the specific needs the project requires.
Contract Development and Manufacturing Organization
specialized for phage-based products
JAFRAL is leading Contract Manufacturer for GMP and non-GMP phage-based products. JAFRAL offers the complete manufacturing related support from screening for the best phage candidate till production of Clinical trial material (CTM) or commercial product for other fields. JAFRAL has experience with development of manufacturing processes for various applications: Human therapeutics, veterinary, food industry and cosmetics. Products can be produced to the highest quality specifications as are > 1E12 PFU/mL and < 1EU/mL.
In addition to that, JAFRAL offers also complete support for analytical testing that is needed for phage-based products. Methods can be developed from start, then optimized and finally verified/validated before routine usage.
JAFRAL has so far produced more than 40 Phage and Cell Banks, 30 Drug Substances and 7 Drug Products that have been successfully used in Clinical Trials.
PhagePro is an early-stage biotechnology therapeutics company that develops bacteriophage-based products to help the world’s most vulnerable communities. Our first product is ProphaLytic-Vc (PVC), which targets cholera prevention in resource-limited settings.